Top

Published in:

01-12-2019 | Prostate Cancer | Editorial

Developments in oligometastatic hormone-sensitive prostate cancer

Authors: Phuoc T. Tran, Piet Ost

Published in: World Journal of Urology | Issue 12/2019

Excerpt

“Suddenly a solitary horseman appeared on the horizon, then another, and another, and then six. In a few moments a whole crowd of solitary horsemen swooped down upon him.” …

Rubin P, Green J (1968) Solitary metastases. C.C. Thomas, Springfield

Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13(1):8–10CrossRef

Palma DA, Salama JK, Lo SS, Senan S, Treasure T, Govindan R et al (2014) The oligometastatic state—separating truth from wishful thinking. Nat Rev Clin Oncol 11(9):549–557CrossRef

Tran PT, Antonarakis ES (2017) Altering the natural history of oligometastatic prostate cancer with local therapies: reality versus illusion. J Oncol Pract 13(1):21–24CrossRef

Chow K, McCoy P, Stuchbery R, Corcoran NM, Hovens CM (2018) Developments in oligometastatic hormone-sensitive prostate cancer. World J Urol 37(12):1. https://doi.org/10.1007/s00345-018-2542-x CrossRef

Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM (2017) Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol 14(1):15–25CrossRef

Dhondt B, De Bleser E, Claeys T, Buelens S, Lumen N, Vandesompele J et al (2018) Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time. World J Urol 37(12):1. https://doi.org/10.1007/s00345-018-2609-8 CrossRef

Lussier YA, Xing HR, Salama JK, Khodarev NN, Huang Y, Zhang Q et al (2011) MicroRNA expression characterizes oligometastasis(es). PLoS One 6(12):e28650CrossRef

Khodarev NN, Pitroda SP, Weichselbaum RR (2015) microRNAs and oligometastasis. Aging (Albany NY) 7(3):146–147CrossRef

10.

Buelens S, De Bleser E, Dhondt B, Verla W, Decaestecker K, Ost P et al (2018) Importance of metastatic volume in prognostic models to predict survival in newly diagnosed metastatic prostate cancer. World J Urol 37(12):1. https://doi.org/10.1007/s00345-018-2449-6 CrossRef

11.

Rowe SP, Gorin MA, Allaf ME, Pienta KJ, Tran PT, Pomper MG et al (2016) PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. Prostate Cancer Prostatic Dis 19(3):223–230CrossRef

12.

Futterer JJ, Surcel C, van den Bergh R, Borgmann H, Briganti A, Gandaglia G et al (2018) Imaging modalities in synchronous oligometastatic prostate cancer. World J Urol 37(12):1. https://doi.org/10.1007/s00345-018-2416-2 CrossRef

13.

Pasoglou V, Michoux N, Van Damme J, Van Nieuwenhove S, Halut M, Triqueneaux P et al (2019) Pattern of metastatic deposit in recurrent prostate cancer: a whole-body MRI-based assessment of lesion distribution and effect of primary treatment. World J Urol 37(12):1. https://doi.org/10.1007/s00345-019-02700-2 CrossRef

14.

Yuan Y, Kishan AU, Nickols NG (2018) Treatment of the primary tumor in metastatic prostate cancer. World J Urol 37(12):1. https://doi.org/10.1007/s00345-018-2552-8 CrossRef

15.

Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S et al (1988) Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61(1):195–202CrossRef

16.

Singh D, Yi WS, Brasacchio RA, Muhs AG, Smudzin T, Williams JP et al (2004) Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys 58(1):3–10CrossRef

17.

Schweizer MT, Zhou XC, Wang H, Yang T, Shaukat F, Partin AW et al (2013) Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Ann Oncol 24(11):2881–2886CrossRef

18.

Sridharan S, Steigler A, Spry NA, Joseph D, Lamb DS, Matthews JH et al (2016) Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial. Radiother Oncol 121(1):98–102CrossRef

19.

Fodor A, Lancia A, Ceci F, Picchio M, Hoyer M, Jereczek-Fossa BA et al (2018) Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row. World J Urol 37(12):1. https://doi.org/10.1007/s00345-018-2322-7 CrossRef

20.

Patel PH, Chaw CL, Tree AC, Sharabiani M, van As NJ (2018) Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer. World J Urol 37(12):1. https://doi.org/10.1007/s00345-019-02873-w CrossRef

21.

Moyer CL, Phillips R, Deek MP, Radwan N, Ross AE, Antonarakis ES et al (2018) Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment. World J Urol 37(12):1. https://doi.org/10.1007/s00345-018-2477-2 CrossRef

22.

Triggiani L, Mazzola R, Magrini SM, Ingrosso G, Borghetti P, Trippa F et al (2018) Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. World J Urol 37(12):1. https://doi.org/10.1007/s00345-019-02717-7 CrossRef

Title: Developments in oligometastatic hormone-sensitive prostate cancer
Authors: Phuoc T. Tran
Piet Ost
Publication date: 01-12-2019
Publisher: Springer Berlin Heidelberg
Keywords: Prostate Cancer
Metastasis
Prostate Cancer
Published in: World Journal of Urology / Issue 12/2019
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-019-03009-w

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Developments in oligometastatic hormone-sensitive prostate cancer

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 12/2019

The risk factors of urinary tract infection after transurethral resection of bladder tumors

Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer

Is there enough evidence to support sacral neuromodulation as a viable treatment option in children and adolescents with neurogenic lower urinary tract dysfunction?

The impact of completeness of last transurethral resection of bladder tumors on the outcomes of radical cystectomy

Pattern of metastatic deposit in recurrent prostate cancer: a whole-body MRI-based assessment of lesion distribution and effect of primary treatment

Prognostic implications of prostatic urethral involvement in non-muscle-invasive bladder cancer